The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

A Hatzakis; V Chulanov; AC Gadano; C Bergin; Z Ben-Ari; J Mossong; I Schreter; O Baatarkhuu; S Acharya; I Aho; AC Anand; MI Andersson; V Arendt; P Arkkila; K Barclay; F Bessone; S Blach; N Blokhina; CR Brunton; G Choudhuri; L Cisneros; EA (Esther) Croes; YA Dahgwahdorj; O Dalgard; JR Daruich; NR Dashdorj; D Davaadorj; Rob de Knegt; M Vree; C Estes; R Flisiak; E Gane; E Gower; W Halota; C Henderson; P Hoffmann; J Hornell; D Houlihan; S Hrusovsky; P Jarcuska; D Kershenobich; K Kostrzewska; P Kristian; M Leshno; Y Lurie; A Mahomed; N Mamonova; N Mendez-Sanchez; S Norris; E Nurmukhametova; P Nymadawa; M Oltman; J Oyunbileg; T Oyunsuren; G Papatheodoridis; N Pimenov; N Prabdial-Sing; M Prins; S Radke; A Rakhmanova; K Razavi-Shearer; HW Reesink; E Ridruejo; R Safadi; O Sagalova; JF Sanchez Avila; R Sanduijav; V Saraswat; C Seguin-Devaux; SR Shah; I Shestakova; A Shevaldin; O Shibolet; MO Silva; S Sokolov; M Sonderup; K Souliotis; CW Spearman; T Staub; C Stedman; EA Strebkova; D Struck; V Sypsa; K Tomasiewicz; L Undram; AJ van der Meer; D van Santen; I Veldhuijzen; FG Villamil; S Willemse; E Zuckerman; FR Zuure; P Puri; H Razavi

doi:10.1111/jvh.12351

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

A Hatzakis, V Chulanov, AC Gadano, C Bergin, Z Ben-Ari, J Mossong, I Schreter, O Baatarkhuu, S Acharya, I Aho, AC Anand, MI Andersson, V Arendt, P Arkkila, K Barclay, F Bessone, S Blach, N Blokhina, CR Brunton, G ChoudhuriL Cisneros, EA (Esther) Croes, YA Dahgwahdorj, O Dalgard, JR Daruich, NR Dashdorj, D Davaadorj, Rob de Knegt, M Vree, C Estes, R Flisiak, E Gane, E Gower, W Halota, C Henderson, P Hoffmann, J Hornell, D Houlihan, S Hrusovsky, P Jarcuska, D Kershenobich, K Kostrzewska, P Kristian, M Leshno, Y Lurie, A Mahomed, N Mamonova, N Mendez-Sanchez, S Norris, E Nurmukhametova, P Nymadawa, M Oltman, J Oyunbileg, T Oyunsuren, G Papatheodoridis, N Pimenov, N Prabdial-Sing, M Prins, S Radke, A Rakhmanova, K Razavi-Shearer, HW Reesink, E Ridruejo, R Safadi, O Sagalova, JF Sanchez Avila, R Sanduijav, V Saraswat, C Seguin-Devaux, SR Shah, I Shestakova, A Shevaldin, O Shibolet, MO Silva, S Sokolov, M Sonderup, K Souliotis, CW Spearman, T Staub, C Stedman, EA Strebkova, D Struck, V Sypsa, K Tomasiewicz, L Undram, AJ van der Meer, D van Santen, I Veldhuijzen, FG Villamil, S Willemse, E Zuckerman, FR Zuure, P Puri, H Razavi

Research output: Contribution to journal › Article › Academic › peer-review

114 Citations (Scopus)

Abstract

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

Original language	Undefined/Unknown
Pages (from-to)	26-45
Number of pages	20
Journal	Journal of Viral Hepatitis
Volume	22
DOIs	https://doi.org/10.1111/jvh.12351
Publication status	Published - 2015

Research programs

EMC MM-04-20-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12351

Cite this

Hatzakis, A., Chulanov, V., Gadano, AC., Bergin, C., Ben-Ari, Z., Mossong, J., Schreter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, AC., Andersson, MI., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, CR., ... Razavi, H. (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. Journal of Viral Hepatitis, 22, 26-45. https://doi.org/10.1111/jvh.12351

@article{5dce66d2045d422e976618045ef75e64,

title = "The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2",

abstract = "Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.",

author = "A Hatzakis and V Chulanov and AC Gadano and C Bergin and Z Ben-Ari and J Mossong and I Schreter and O Baatarkhuu and S Acharya and I Aho and AC Anand and MI Andersson and V Arendt and P Arkkila and K Barclay and F Bessone and S Blach and N Blokhina and CR Brunton and G Choudhuri and L Cisneros and Croes, {EA (Esther)} and YA Dahgwahdorj and O Dalgard and JR Daruich and NR Dashdorj and D Davaadorj and {de Knegt}, Rob and M Vree and C Estes and R Flisiak and E Gane and E Gower and W Halota and C Henderson and P Hoffmann and J Hornell and D Houlihan and S Hrusovsky and P Jarcuska and D Kershenobich and K Kostrzewska and P Kristian and M Leshno and Y Lurie and A Mahomed and N Mamonova and N Mendez-Sanchez and S Norris and E Nurmukhametova and P Nymadawa and M Oltman and J Oyunbileg and T Oyunsuren and G Papatheodoridis and N Pimenov and N Prabdial-Sing and M Prins and S Radke and A Rakhmanova and K Razavi-Shearer and HW Reesink and E Ridruejo and R Safadi and O Sagalova and {Sanchez Avila}, JF and R Sanduijav and V Saraswat and C Seguin-Devaux and SR Shah and I Shestakova and A Shevaldin and O Shibolet and MO Silva and S Sokolov and M Sonderup and K Souliotis and CW Spearman and T Staub and C Stedman and EA Strebkova and D Struck and V Sypsa and K Tomasiewicz and L Undram and {van der Meer}, AJ and {van Santen}, D and I Veldhuijzen and FG Villamil and S Willemse and E Zuckerman and FR Zuure and P Puri and H Razavi",

year = "2015",

doi = "10.1111/jvh.12351",

language = "Undefined/Unknown",

volume = "22",

pages = "26--45",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Hatzakis, A, Chulanov, V, Gadano, AC, Bergin, C, Ben-Ari, Z, Mossong, J, Schreter, I, Baatarkhuu, O, Acharya, S, Aho, I, Anand, AC, Andersson, MI, Arendt, V, Arkkila, P, Barclay, K, Bessone, F, Blach, S, Blokhina, N, Brunton, CR, Choudhuri, G, Cisneros, L, Croes, EA, Dahgwahdorj, YA, Dalgard, O, Daruich, JR, Dashdorj, NR, Davaadorj, D, de Knegt, R, Vree, M, Estes, C, Flisiak, R, Gane, E, Gower, E, Halota, W, Henderson, C, Hoffmann, P, Hornell, J, Houlihan, D, Hrusovsky, S, Jarcuska, P, Kershenobich, D, Kostrzewska, K, Kristian, P, Leshno, M, Lurie, Y, Mahomed, A, Mamonova, N, Mendez-Sanchez, N, Norris, S, Nurmukhametova, E, Nymadawa, P, Oltman, M, Oyunbileg, J, Oyunsuren, T, Papatheodoridis, G, Pimenov, N, Prabdial-Sing, N, Prins, M, Radke, S, Rakhmanova, A, Razavi-Shearer, K, Reesink, HW, Ridruejo, E, Safadi, R, Sagalova, O, Sanchez Avila, JF, Sanduijav, R, Saraswat, V, Seguin-Devaux, C, Shah, SR, Shestakova, I, Shevaldin, A, Shibolet, O, Silva, MO, Sokolov, S, Sonderup, M, Souliotis, K, Spearman, CW, Staub, T, Stedman, C, Strebkova, EA, Struck, D, Sypsa, V, Tomasiewicz, K, Undram, L, van der Meer, AJ, van Santen, D, Veldhuijzen, I, Villamil, FG, Willemse, S, Zuckerman, E, Zuure, FR, Puri, P & Razavi, H 2015, 'The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2', Journal of Viral Hepatitis, vol. 22, pp. 26-45. https://doi.org/10.1111/jvh.12351

TY - JOUR

T1 - The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

AU - Hatzakis, A

AU - Chulanov, V

AU - Gadano, AC

AU - Bergin, C

AU - Ben-Ari, Z

AU - Mossong, J

AU - Schreter, I

AU - Baatarkhuu, O

AU - Acharya, S

AU - Aho, I

AU - Anand, AC

AU - Andersson, MI

AU - Arendt, V

AU - Arkkila, P

AU - Barclay, K

AU - Bessone, F

AU - Blach, S

AU - Blokhina, N

AU - Brunton, CR

AU - Choudhuri, G

AU - Cisneros, L

AU - Croes, EA (Esther)

AU - Dahgwahdorj, YA

AU - Dalgard, O

AU - Daruich, JR

AU - Dashdorj, NR

AU - Davaadorj, D

AU - de Knegt, Rob

AU - Vree, M

AU - Estes, C

AU - Flisiak, R

AU - Gane, E

AU - Gower, E

AU - Halota, W

AU - Henderson, C

AU - Hoffmann, P

AU - Hornell, J

AU - Houlihan, D

AU - Hrusovsky, S

AU - Jarcuska, P

AU - Kershenobich, D

AU - Kostrzewska, K

AU - Kristian, P

AU - Leshno, M

AU - Lurie, Y

AU - Mahomed, A

AU - Mamonova, N

AU - Mendez-Sanchez, N

AU - Norris, S

AU - Nurmukhametova, E

AU - Nymadawa, P

AU - Oltman, M

AU - Oyunbileg, J

AU - Oyunsuren, T

AU - Papatheodoridis, G

AU - Pimenov, N

AU - Prabdial-Sing, N

AU - Prins, M

AU - Radke, S

AU - Rakhmanova, A

AU - Razavi-Shearer, K

AU - Reesink, HW

AU - Ridruejo, E

AU - Safadi, R

AU - Sagalova, O

AU - Sanchez Avila, JF

AU - Sanduijav, R

AU - Saraswat, V

AU - Seguin-Devaux, C

AU - Shah, SR

AU - Shestakova, I

AU - Shevaldin, A

AU - Shibolet, O

AU - Silva, MO

AU - Sokolov, S

AU - Sonderup, M

AU - Souliotis, K

AU - Spearman, CW

AU - Staub, T

AU - Stedman, C

AU - Strebkova, EA

AU - Struck, D

AU - Sypsa, V

AU - Tomasiewicz, K

AU - Undram, L

AU - van der Meer, AJ

AU - van Santen, D

AU - Veldhuijzen, I

AU - Villamil, FG

AU - Willemse, S

AU - Zuckerman, E

AU - Zuure, FR

AU - Puri, P

AU - Razavi, H

PY - 2015

Y1 - 2015

N2 - Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

AB - Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

U2 - 10.1111/jvh.12351

DO - 10.1111/jvh.12351

M3 - Article

C2 - 25560840

SN - 1352-0504

VL - 22

SP - 26

EP - 45

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

ER -